Gan & Lee Pharmaceuticals. (603087.SS)
CNY 45.28
(0.67%)
CNY 45.28
(0.67%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 78.98 Million CNY | 397.07% |
| 2022 | 15.89 Million CNY | -21.02% |
| 2021 | 20.12 Million CNY | 121.4% |
| 2020 | 9.08 Million CNY | -76.32% |
| 2019 | 38.37 Million CNY | 7.0% |
| 2018 | 35.86 Million CNY | 32.42% |
| 2017 | 27.08 Million CNY | -21.75% |
| 2016 | 34.61 Million CNY | -57.49% |
| 2015 | 81.42 Million CNY | 308.13% |
| 2014 | 19.95 Million CNY | 395.24% |
| 2013 | 4.02 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 6.2 Million CNY | -92.15% |
| 2024 Q3 | 2.36 Million CNY | -98.11% |
| 2024 Q2 | 194.21 Million CNY | 3031.73% |
| 2023 FY | 78.98 Million CNY | 397.07% |
| 2023 Q1 | 17.02 Million CNY | 7.15% |
| 2023 Q3 | 23.45 Million CNY | 9.18% |
| 2023 Q4 | 78.98 Million CNY | 236.75% |
| 2023 Q2 | 21.48 Million CNY | 26.17% |
| 2022 Q3 | 20.63 Million CNY | 0.46% |
| 2022 Q1 | 19.62 Million CNY | -2.48% |
| 2022 FY | 15.89 Million CNY | -21.02% |
| 2022 Q4 | 15.89 Million CNY | -23.0% |
| 2022 Q2 | 20.54 Million CNY | 4.7% |
| 2021 Q1 | 20.42 Million CNY | 124.76% |
| 2021 Q3 | 17.41 Million CNY | -7.34% |
| 2021 Q2 | 18.79 Million CNY | -7.97% |
| 2021 Q4 | 20.12 Million CNY | 15.51% |
| 2021 FY | 20.12 Million CNY | 121.4% |
| 2020 Q3 | 25.43 Million CNY | -11.09% |
| 2020 FY | 9.08 Million CNY | -76.32% |
| 2020 Q1 | 31.04 Million CNY | -19.08% |
| 2020 Q4 | 9.08 Million CNY | -64.27% |
| 2020 Q2 | 28.6 Million CNY | -7.88% |
| 2019 FY | 38.37 Million CNY | 7.0% |
| 2019 Q1 | - CNY | 0.0% |
| 2019 Q4 | 38.37 Million CNY | 0.0% |
| 2018 FY | 35.86 Million CNY | 32.42% |
| 2017 Q1 | - CNY | 0.0% |
| 2017 FY | 27.08 Million CNY | -21.75% |
| 2017 Q4 | 27.08 Million CNY | 0.0% |
| 2017 Q2 | 37.17 Million CNY | 0.0% |
| 2016 FY | 34.61 Million CNY | -57.49% |
| 2015 FY | 81.42 Million CNY | 308.13% |
| 2014 FY | 19.95 Million CNY | 395.24% |
| 2013 FY | 4.02 Million CNY | 0.0% |